drugset / Trial / NCT00860496
A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers
Parallel-groupOpen-labelPrevention
Summary
A new immunosuppressive drug, based on the inhibition of important enzymes in the immune system, called JAK, is being developed by Pfizer to prevent transplant rejection. Since many treatments for transplant rejection may be administered together, this research study will analyze the effects of common transplant rejection therapies, Tacrolimus and Cyclosporine, on the JAK inhibitor, CP-690,550.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 200 mg | — |
| Subject | Tacrolimus | Small molecule | 5 mg | — |
| Subject | Tofacitinib | Small molecule | 10 mg | — |
Indications
No indication recorded.